REGINA Data Support Further Evaluation of Neoadjuvant Regorafenib, Nivolumab, and SCRT in Rectal Cancer
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer
Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer
First-Line Tislelizumab Plus Chemotherapy Shows OS Benefit in PD-L1+ ESCC Subgroups
2 Commerce Drive
Cranbury, NJ 08512